Literature DB >> 2788277

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

H G Göttlinger1, J G Sodroski, W A Haseltine.   

Abstract

The effects on human immunodeficiency virus type 1 virion morphogenesis and on virus replication of mutations that affect posttranslational processing of the capsid precursor protein are described. A change in the glycine residue at position two from the N terminus abolishes the myristoylation of the precursor proteins and also prevents virus particle release. Mutations in the viral protease gene abolish proteolytic cleavage of the capsid precursor but do not prevent the formation and budding of virion particles of immature appearance. Mutations that alter the sequence of the sites normally used for cleavage of the major capsid protein p24 from the capsid precursor alter virion morphogenesis and prevent virus replication.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788277      PMCID: PMC297714          DOI: 10.1073/pnas.86.15.5781

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

Authors:  R A Kramer; M D Schaber; A M Skalka; K Ganguly; F Wong-Staal; E P Reddy
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

4.  Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.

Authors:  A Rein; M R McClure; N R Rice; R B Luftig; A M Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

6.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

7.  Functional role of human immunodeficiency virus type 1 vpu.

Authors:  E F Terwilliger; E A Cohen; Y C Lu; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.

Authors:  H R Gelderblom; E H Hausmann; M Ozel; G Pauli; M A Koch
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

View more
  406 in total

1.  Membrane association induces a conformational change in the Ebola virus matrix protein.

Authors:  S Scianimanico; G Schoehn; J Timmins; R H Ruigrok; H D Klenk; W Weissenhorn
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

2.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions.

Authors:  J B Bowzard; J W Wills; R C Craven
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Role of RNA in facilitating Gag/Gag-Pol interaction.

Authors:  Ahmad Khorchid; Rabih Halwani; Mark A Wainberg; Lawrence Kleiman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera.

Authors:  J B Bowzard; R J Visalli; C B Wilson; J S Loomis; E M Callahan; R J Courtney; J W Wills
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Functional analysis of protein N-myristoylation: metabolic labeling studies using three oxygen-substituted analogs of myristic acid and cultured mammalian cells provide evidence for protein-sequence-specific incorporation and analog-specific redistribution.

Authors:  D R Johnson; A D Cox; P A Solski; B Devadas; S P Adams; R M Leimgruber; R O Heuckeroth; J E Buss; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.